Nemes Rush Group LLC Denali Therapeutics Inc. Call Options Transaction History
Nemes Rush Group LLC
- $689 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DNLI
# of Institutions
228Shares Held
120MCall Options Held
60.6KPut Options Held
48.4K-
Baillie Gifford & CO13.3MShares$325 Million0.3% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$321 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$272 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$261 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.91MShares$193 Million0.05% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.27B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...